Latest news with #ReynoldLemkinsGroup
Business Wire
6 days ago
- Business
- Business Wire
Reynold Lemkins Drives Cross-Border Deep Tech Investment, Featured Prominently at Asia's Leading Capital and Innovation Forums
HONG KONG & MACAU--(BUSINESS WIRE)--Reynold Lemkins Group, a global investment firm known for its long-term cross-border capital strategy, made a notable impact this May at two of Asia's premier events: the Greenwich Economic Forum (GEF) Hong Kong and BEYOND Expo 2025 in Macau. At GEF Hong Kong, Reynold Lemkins Asia Chief Investment Officer Kris Haoran Liu was invited to speak on a high-level roundtable titled 'Family Office Investment Outlook', moderated by Tae Yoo, Managing Director of Hong Kong Exchanges and Clearing (HKEX). Liu emphasized IPO as not merely an exit but a strategic entry point into long-term value creation, especially in sectors undergoing structural transformation. He also highlighted Hong Kong's pivotal role as a pricing anchor for global capital. The forum, which brought together global financial leaders including Nouriel Roubini (Chairman & CEO, Roubini Macro Associates), Kenny Lam (CEO, Two Sigma Asia Pacific), and Jan Boomaars (CEO, Optiver), underscored the rising relevance of Asia—especially Hong Kong—in the evolving landscape of alternative investments, economic realignment, and tech-led growth. In Macau, at BEYOND Expo 2025 —Asia's largest tech innovation summit—Reynold Lemkins took part as a Legacy Partner, hosting private sessions with deep tech founders, researchers, and institutional LPs. The firm engaged across verticals including AI, advanced manufacturing, robotics, and frontier healthtech, reinforcing its thesis of value-backed, scalable innovation across borders. 'Reynold Lemkins Group demonstrated clear conviction in identifying globally relevant tech solutions, from regulatory-ready biotech platforms to next-gen energy systems and smart infrastructure,' commented a tech investor familiar with the firm's presence in Macau. Recent investments reflect this diversified thesis. In addition to health-focused companies like Cloudbreak Pharma and VISEN Pharmaceuticals, the firm has also actively supported high-growth industrial and AI ventures such as Contemporary Amperex Technology (CATL), Sanhua Intelligent Controls, and Unisound, exemplifying its multi-sector strategy across late-stage and semi-public market opportunities. To learn more, visit follow Reynold Lemkins on LinkedIn, or explore insights via Medium.
Business Wire
6 days ago
- Business
- Business Wire
Reynold Lemkins Group Catalyzes Global Biotech Innovation as Cornerstone Investor in Recent HKEX Listing
HONG KONG--(BUSINESS WIRE)--Reynold Lemkins Group, a leading global investment firm focused on late-stage growth and frontier technologies, announced its significant cornerstone investment in the initial public offering (IPO) of Cloudbreak Pharma ( on the Hong Kong Stock Exchange (HKEX). This strategic investment underscores Reynold Lemkins Group's commitment to backing visionary biotech companies poised to deliver transformative solutions to global challenges. Reynold Lemkins Group serves as a cornerstone investor in Cloudbreak Pharma's HKEX IPO, reinforcing its commitment to bridging cross-border capital with transformative growth. Cloudbreak Pharma, a clinical-stage ophthalmic biotechnology company, recently completed its HKD 612 million growth-focused IPO. Focused on innovative therapies like CBT-001 for pterygium (in Phase 3 U.S./China trials and potentially the world's first approved non-surgical treatment), Cloudbreak Pharma will utilize proceeds to fund critical R&D, manufacturing expansion, and commercialization of its lead biologic assets. Reynold Lemkins Group served as a cornerstone investor, committing USD 22.8 million (HKD 179 million) to the offering alongside Wealth Strategy Holding, with collective cornerstone investment totaling approximately USD 45.6 million. Reynold Lemkins Group's role as a cornerstone investor in this HKEX listing further solidifies its position as a crucial cross-border capital partner. The firm leverages its deep expertise in navigating complex international markets to connect promising innovation from Asia with global investment, facilitating the growth of companies that are redefining industries worldwide. This strategic focus is underscored by the firm's consistent track record in the biotech sector, including its prior participation in the successful IPO of VISEN Pharmaceuticals (HKEX: 02561), which similarly attracted strong institutional demand and aligned with Reynold Lemkins' commitment to regulatory-validated, commercially scalable businesses. This investment exemplifies Reynold Lemkins Group's strategy of providing patient, strategic capital to ventures at the forefront of technological and medical advancement, ensuring their ability to scale and deliver. "Cloudbreak Pharma epitomizes Reynold Lemkins Group's core philosophy: empowering companies that are truly transforming their fields," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "We're proud to back a biotech pioneer bringing life-changing science to global health. This investment perfectly aligns with our drive to bridge cross-border capital with transformative growth, creating lasting value."
Yahoo
10-06-2025
- Business
- Yahoo
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG, June 10, 2025--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. "Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "Biotech firms entering public markets need partners who understand both the science and the structure of global growth." With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium. View source version on Contacts Reynold Lemkins Groupreynoldlemkins@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
10-06-2025
- Business
- Business Wire
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG--(BUSINESS WIRE)-- Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. Bridging East and West in biotech investing, Reynold Lemkins backs science-driven companies with cross-border capital and global scale strategies. Share As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. 'Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale,' said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. 'Biotech firms entering public markets need partners who understand both the science and the structure of global growth.' With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium.
